Stocks are virtually unchanged following a deluge of domestic economic data this morning.
Great strides are being made at these off-the-radar drug development companies. Here are 3 emerging players to watch.
Capital One is both upgraded and downgraded, and Visa is downgraded to 'neutral.'
TheStreet's Adam Feuerstein gazes into his crystal ball to offer his biotechnology forecast for the new year.
The averages remain in a narrow trading range, as investors await movement in the ongoing fiscal cliff negotiations.
The biotech's partner says the vaccine didn't meet a study goal to show effectiveness. Stock drops almost 60%.
Clinical trials, drug launches and FDA approval decisions fill the calendar for these companies at the start of the new year.
VIDEO ON MSN MONEY
Copyright © 2013 Microsoft. All rights reserved.
Quotes are real-time for NASDAQ, NYSE and AMEX. See delay times for other exchanges.
The Market Dispatches column has been discontinued. Here's where to find the latest stock and business news on MSN Money, and the latest from market writer Charley Blaine.
MONEY & POLITICS
Breaking up big banks is an untested solution to the too big to fail problem that attempts to isolate and dismantle large, troubled institutions while protecting the rest of the economy.
The IRS is struggling to combat identify thieves who file fraudulent tax returns in the names of older residents who don't need to file.